aTYR PHARMA (ATYR) Equity Ratio (2019 - 2025)
Historic Equity Ratio for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to 0.75.
- aTYR PHARMA's Equity Ratio rose 580.96% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year increase of 580.96%. This contributed to the annual value of 0.72 for FY2024, which is 376.39% down from last year.
- aTYR PHARMA's Equity Ratio amounted to 0.75 in Q3 2025, which was up 580.96% from 0.74 recorded in Q2 2025.
- In the past 5 years, aTYR PHARMA's Equity Ratio ranged from a high of 0.95 in Q3 2021 and a low of 0.71 during Q3 2024
- In the last 5 years, aTYR PHARMA's Equity Ratio had a median value of 0.79 in 2023 and averaged 0.81.
- As far as peak fluctuations go, aTYR PHARMA's Equity Ratio surged by 2269.43% in 2021, and later tumbled by 2120.79% in 2022.
- aTYR PHARMA's Equity Ratio (Quarter) stood at 0.94 in 2021, then dropped by 21.21% to 0.74 in 2022, then grew by 0.97% to 0.75 in 2023, then dropped by 3.76% to 0.72 in 2024, then increased by 4.04% to 0.75 in 2025.
- Its last three reported values are 0.75 in Q3 2025, 0.74 for Q2 2025, and 0.77 during Q1 2025.